Screener
BioMarin Pharmaceuticals BMRN Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| ASSETS | June 30, 2026 / (unaudited) | December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Total assets | $11,723,442 | $7,594,022 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $1,005,793 | $759,031 |
| Current portion of long-term debt, net | 658,203 | — |
| Total current liabilities | 1,663,996 | 759,031 |
| Noncurrent liabilities: | ||
| Long-term debt, net | 3,527,939 | 597,176 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's accounts payable?
- BioMarin Pharmaceuticals (BMRN) reported accounts payable of $1.01B in Q2 2026.
- How has BioMarin Pharmaceuticals's accounts payable changed year-over-year?
- BioMarin Pharmaceuticals's accounts payable increased by 47.0% year-over-year, from $684.25M to $1.01B.
- What is the long-term trend for BioMarin Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's accounts payable has grown at a 9.0% compound annual growth rate (CAGR), from $492.55M to $759.03M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about BioMarin Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude